The activation of poly(ADP-ribose) polymerase (PARP) is now considered a final common effector in various types of tissue injury including systemic inflammation, circulatory shock and ischemia/reperfusion. Free radical and oxidant production and related cytotoxicity during ischemia/reperfusion leads to DNA strand breakage which activates the nuclear enzyme PARP and initiates an energy-consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. During the last 5 years, a growing number of experimental studies demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clinical large animal models of regional and global ischemia/reperfusion injury. The objective of the current review is to provide an overview of the experimental evidence implicating PARP as a pathophysiological modulator of myocardial injury in vitro and in vivo. © 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Szabó, G., Liaudet, L., Hagl, S., & Szabó, C. (2004, February 15). Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovascular Research. https://doi.org/10.1016/j.cardiores.2003.09.029